Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 14, 2021, Kaleido Biosciences, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting") to consider and vote on the two proposals set forth below, each of which is described in greater detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on May 5, 2021. The final voting results are set forth below.

Proposal 1 - Election of Directors

The stockholders elected each of the three persons named below to serve as a Class II director of the Company for a three-year term that expires at the Company's annual meeting of stockholders in 2024 and until his or her successor has been duly elected and qualified, subject to his or her earlier death, resignation or removal. The results of such vote were as follows:





Director Name           Votes For        Votes Withheld
Daniel L. Menichella     32,019,324           57,924
Jean Mixer               31,639,786           437,462
Anthony Quinn            29,628,582          2,448,666

Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm

The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021. The results of such vote were as follows:




  Votes For        Votes Against       Abstentions
  35,467,517          112,722            10,393


Item 8.01. Other Events.

On June 17, 2021, the Company will deliver a corporate presentation at the JMP Securities Life Sciences Conference at 4:00 P.M. A copy of the deck attached hereto as Exhibit 99.1 will be utilized in the presentation. An updated version of the Company's corporate presentation will also be available in the investor relations section of the Company's website at http://kaleido.com.

The information provided in Item 8.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

--------------------------------------------------------------------------------

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits:



Exhibit No.   Description

99.1            Corporate slide presentation of the Company, dated June 2021.
104           Cover Page Interactive Data File (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses